BeiGene Expands Management Team with Two Strategic Senior Positions
- Jason Yang, M.D., Ph.D., appointed Senior Vice President of Clinical Development & Operations and Wendy Yan, Senior Vice President of Regulatory Affairs -
- New additions strengthen BeiGene leadership team and bring deep global clinical development and regulatory expertise -
BEIJING--(BUSINESS WIRE)--BeiGene (Beijing), Co., Ltd., an innovative oncology company focused on developing targeted and immune-oncology therapeutics, today announced the additions of two senior members to the Company’s management team. Jason Yang, M.D., Ph.D., joins BeiGene as the Senior Vice President of Clinical Development and Operations, and Wendy Yan joins the Company as Senior Vice President of Regulatory Affairs.
“We are excited to welcome Jason and Wendy to our team, and look forward to harnessing their deep expertise in clinical development and regulatory affairs to strengthen our leadership team and further solidify our position as a leading and innovative oncology company”
“We are excited to welcome Jason and Wendy to our team, and look forward to harnessing their deep expertise in clinical development and regulatory affairs to strengthen our leadership team and further solidify our position as a leading and innovative oncology company,” commented John V. Oyler, Chief Executive Officer of BeiGene. “Jason’s in-depth expertise in oncology R&D will drive our rapid clinical development plan, including our three drug candidates already in Phase 1 trials; and Wendy’s extensive experience in China and global regulatory affairs will be invaluable to the Company as we continue to advance our lead compounds toward potential approvals and pursue our mission of developing life-saving cancer therapeutics for patients.”
Dr. Jason Yang brings more than 16 years of biopharmaceutical R&D experience in oncology to BeiGene, joining the company from Covance, where he previously served as Medical Director in Oncology. Before that, he was a Senior Principal Scientist in cancer biomarker and translational medicine at Pfizer for 7 years, and prior to that he served as a research scientist in cancer genomics at Tularik/Amgen for 6 years. Dr. Yang earned a Ph.D. in Molecular Genetics and Biochemistry from UT Southwestern while conducting cutting edge research on cholesterol transcription regulation with Nobel Laureates Drs. Michael Brown and Joseph Goldstein, an M.S. in Medicine from Nanjing Medical University, and a Medical Degree from Hubei Medical College, Xianning. He conducted his Post-Doctoral research in Chemical Biology with Dr. Stuart Schreiber at Harvard University.
Ms. Wendy Yan brings more than 18 years of China and global regulatory affairs experience to the company, joining BeiGene from her prior position as Global Regulatory Strategist at Bayer Healthcare, where she also previously served as the Director, Head of Regulatory Affairs for China. Since 1996, Ms. Yan has held a number of senior positions in regulatory affairs at multiple global pharmaceutical companies including GlaxoSmithKline, AstraZeneca and Bayer Healthcare. She started her career at the Beijing Drug Control Institute and is a pharmacist by training, having graduated from Beijing Traditional Chinese Medicine University. She also earned a M.B.A. from Staffordshire University.
About BeiGene (Beijing), Co., Ltd.
BeiGene is an innovative Chinese oncology R&D company focused on discovering, developing and commercializing targeted and immune-oncology therapeutics through a novel translational research platform that leverages our strong internal oncology biology expertise with unique access to large number of patient-derived tumor biopsies. With a team of 150 scientists and staff, its pipeline is comprised of novel oral small molecules and monoclonal antibodies for cancer. BeiGene Ltd. is a Cayman Islands exempted company that is an investor in and collaborator with BeiGene (Beijing), Co. Ltd. For more information, please visit our website at www.beigene.com.